Bladder Cancer: Avelumab Maintenance Shows Benefit for Both Patients With and Without Diabetes Mellitus
In this MEDtalk, Dr. Petros Grivas presents the long-term outcomes from the JAVELIN Bladder 100 trial, discussing the impact of avelumab as first-line maintenance therapy for advanced urothelial carcinoma in patients with and without diabetes.